Zhitong Finance APP reported that Baixinan-B (02185) announced that the results of the Iberis-HTN study, titled "Efficacy and safety of catheter-based radiofrequency renal denervation in Chinese patients with uncontrolled hypertension: the randomized, sham-controlled, multi-center Iberis-HTN trial," have been published in Circulation. The Iberis-HTN study is a key trial for our RDN product, the Iberis renal nerve block system, in China.

Renal denervation (RDN) can reduce blood pressure in patients with hypertension, whether or not they are receiving medication. The Iberis-HTN study is a sham-controlled trial conducted in China, aimed at assessing the safety and efficacy of a novel multi-electrode radiofrequency RDN catheter system in patients who remain uncontrolled in hypertension after standardized triple drug treatment. This study shows that RDN is safe in this trial of Chinese patients who remain uncontrolled in hypertension after standardized triple drug treatment, and it can reduce dynamic blood pressure and clinic blood pressure after six months compared to the sham control group.

Professor Jiang Xiongjing and Professor Felix Mahfoud made equal contributions to this literature, both serving as co-first authors, while Academician Gao Runlin acted as the correspondence author.

The company's founder and CEO Wang Li stated: "I am pleased to see our Iberis-HTN trial results published in Circulation. This is also the first time we have published a trial concerning renal nerve denervation performed via the transradial approach (TRA). TRA makes RDN safer, more effective, and more economical. Our ultimate goal is to provide day surgery treatment for renal sympathetic nerve ablation for global patients."